Glucose Control Therapies
This resource on Type 1 Diabetes Research was created in partnership with JDRF, an active partner of Beyond Type 1 at the time of publication, through the JDRF – Beyond Type 1 Alliance.
Finding simpler and more advanced ways to help people living with type 1 diabetes control their blood glucose levels is one of the best ways to improve lives today. With recent advances in technology, approval of hybrid-closed loop systems and new drug classes being investigated, there has never been a better time to have diabetes. Glucose control therapy research focuses three core areas:
- Artificial pancreas (AP) technologies such as the recently approved Control-IQ from Tandem Diabetes Care
- Next-generation insulin classes such as ultra-fast insulin, and “smart” insulin that can automatically react to the changes in the blood glucose levels
- Investigation into other drug classes such as SGLT inhibitors to improve blood glucose management
Helping people with type 1 diabetes (T1D) manage their blood glucose levels not only lowers the risk for future complications, it makes every day easier to get through without constantly worrying about your numbers!
Glucose Control Therapies: The Latest News
vTv Therapeutics Announces Positive Study Results of Potential First-in-Class Oral Adjunctive Therapy for T1D
On February 10, vTv Therapeutics announced positive study results from the second part of the Phase 2 Simplici-T1 Study of TTP399.MORE
JDRF CEO to Health Insurers: Cover New Technology
JDRF President & CEO Aaron Kowalski, Ph.D calls on insurers to cover FDA approved type 1 diabetes technologyMORE
Tandem’s Control-IQ Hybrid Closed Loop Approved by the FDA
The FDA announced the approval of the Control-IQ Hybrid Closed Loop System from Tandem Diabetes Care. The system sees the t:slim X2 insulin pump and Dexcom G6 continuous glucose monitor working togeth...MORE
Exciting Trial Results for Tandem’s Control-IQ Hybrid Closed Loop System
Participants using Control-IQ saw an increased time in range, lowered HbA1c, and less time in hyperglycemia and hypoglycemia.MORE
Tidepool and Medtronic Announce Collaboration on Interoperable Automated Insulin Pump
Tidepool announced that they have partnered with Medtronic to create an interoperable automated insulin pump system.MORE
European Commission Approves Zynquista, First Dual SGLT Inhibitor for T1D
Zynquista is the first dual SGLT1 and SGLT2 inhibitor approved for use in Type 1 diabetes, and the second oral medication approved for use in Type 1 diabetes. MOREGlucose Control Therapies: Trials
To learn more about all the great T1D research being funded by JDRF, visit their research and impact page here.
